.jpg)
1 hour ago
3
Article content
Proposed $1.0 Million Convertible Debenture and Warrant Financing and
Concurrent Common Share Private Placement Up to $1.0 Million
Intended to Support Near-Term Operations
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that its previously announced financing has been upsized up to approximately $2 million.
Article content
Article content
Article content
On January 27th, the Company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0 million in the Company by way of a non-brokered private placement (the “Debenture Private Placement”) of an unsecured convertible debenture and two million common share purchase warrants. The Company anticipates that key terms of the convertible debenture would include:
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- a maturity date of January 28, 2029;
Article content
- a conversion price of $0.20 per common share; and
Article content
- an interest rate of 12% per annum payable semi-annually in cash.
Article content
Each warrant would be exercisable at $0.20 per common share until January 28, 2029, subject to customary adjustments. A subsequent news release will be issued in connection with the Debenture Private Placement once financing terms have been finalized.
Article content
Concurrently with the Debenture Private Placement, the Company proposes to offer up to 8,333,334 common shares at a price of $0.12 per share for additional gross proceeds of up to approximately $1.0 million by way of a non-brokered private placement (the “Common Share Private Placement” and, together with the Debenture Private Placement, the “Private Placements”). As consideration for services provided in connection with the Common Share Private Placement, the Company may pay a finder’s fee to certain eligible finders who introduce subscribers to the financing.
Article content
Article content
The terms of the Private Placements, as announced in the Company’s news release dated January 27, 2026, otherwise remain unchanged.
Article content
The Company intends to use the aggregate gross proceeds of the Private Placements to provide near-term working capital to support ongoing corporate activities and strategic initiatives while the Company continues to evaluate longer-term financing alternatives.
Article content
Closing of the Private Placements is subject to the Company obtaining all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange, and entry into definitive subscription agreements. Pursuant to applicable Canadian securities laws, all securities issued in connection with the Private Placements will be subject to a statutory hold period of four months plus a day from the date of issuance.
Article content
About Rakovina Therapeutics Inc.
Article content
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
English (US)